INTRODUCTION: Oncogenic RET tyrosine kinase gene fusions and activating mutations have recently been identified in lung cancers, prompting initiation of targeted therapy trials in this disease. Although RET point mutation has been identified as a driver of tumorigenesis in medullary thyroid carcinoma (MTC), no fusions have been described to date. OBJECTIVE: We evaluated the role of RET fusion as an oncogenic driver in MTC. METHODS: We describe a patient who died from aggressive sporadic MTC < 10 months after diagnosis. Her tumor was evaluated by means of next-generation sequencing, including an intronic capture strategy. RESULTS: A reciprocal translocation involving RET intron 12 was identified. The fusion was validated using a targeted break apart fluorescence in situ hybridization probe, and RNA sequencing confirmed the existence of an in-frame fusion transcript joining MYH13 exon 35 with RET exon 12. Ectopic expression of fusion product in a murine Ba/F3 cell reporter model established strong oncogenicity. Three tyrosine kinase inhibitors currently used to treat MTC in clinical practice blocked tumorigenic cell growth. CONCLUSION: This finding represents the report of a novel RET fusion, the first of its kind described in MTC. The finding of this potential novel oncogenic mechanism has clear implications for sporadic MTC, which in the majority of cases has no driver mutation identified. The presence of a RET fusion also provides a plausible target for RET tyrosine kinase inhibitor therapies.
INTRODUCTION: Oncogenic RET tyrosine kinase gene fusions and activating mutations have recently been identified in lung cancers, prompting initiation of targeted therapy trials in this disease. Although RET point mutation has been identified as a driver of tumorigenesis in medullary thyroid carcinoma (MTC), no fusions have been described to date. OBJECTIVE: We evaluated the role of RET fusion as an oncogenic driver in MTC. METHODS: We describe a patient who died from aggressive sporadic MTC < 10 months after diagnosis. Her tumor was evaluated by means of next-generation sequencing, including an intronic capture strategy. RESULTS: A reciprocal translocation involving RET intron 12 was identified. The fusion was validated using a targeted break apart fluorescence in situ hybridization probe, and RNA sequencing confirmed the existence of an in-frame fusion transcript joining MYH13 exon 35 with RET exon 12. Ectopic expression of fusion product in a murine Ba/F3 cell reporter model established strong oncogenicity. Three tyrosine kinase inhibitors currently used to treat MTC in clinical practice blocked tumorigenic cell growth. CONCLUSION: This finding represents the report of a novel RET fusion, the first of its kind described in MTC. The finding of this potential novel oncogenic mechanism has clear implications for sporadic MTC, which in the majority of cases has no driver mutation identified. The presence of a RET fusion also provides a plausible target for RET tyrosine kinase inhibitor therapies.
Authors: Thomas Wiesner; Jie He; Roman Yelensky; Rosaura Esteve-Puig; Thomas Botton; Iwei Yeh; Doron Lipson; Geoff Otto; Kristina Brennan; Rajmohan Murali; Maria Garrido; Vincent A Miller; Jeffrey S Ross; Michael F Berger; Alyssa Sparatta; Gabriele Palmedo; Lorenzo Cerroni; Klaus J Busam; Heinz Kutzner; Maureen T Cronin; Philip J Stephens; Boris C Bastian Journal: Nat Commun Date: 2014 Impact factor: 14.919
Authors: Funda Meric-Bernstam; Garrett M Frampton; Jaime Ferrer-Lozano; Roman Yelensky; Jose A Pérez-Fidalgo; Ying Wang; Gary A Palmer; Jeffrey S Ross; Vincent A Miller; Xiaoping Su; Pilar Eroles; Juan Antonio Barrera; Octavio Burgues; Ana M Lluch; Xiaofeng Zheng; Aysegul Sahin; Philip J Stephens; Gordon B Mills; Maureen T Cronin; Ana M Gonzalez-Angulo Journal: Mol Cancer Ther Date: 2014-03-07 Impact factor: 6.261
Authors: Jean J Zhao; Zhenning Liu; Li Wang; Eyoung Shin; Massimo F Loda; Thomas M Roberts Journal: Proc Natl Acad Sci U S A Date: 2005-12-08 Impact factor: 11.205
Authors: Yoram Cohen; Mingzhao Xing; Elizabeth Mambo; Zhongmin Guo; Guogun Wu; Barry Trink; Uziel Beller; William H Westra; Paul W Ladenson; David Sidransky Journal: J Natl Cancer Inst Date: 2003-04-16 Impact factor: 13.506
Authors: Hengyu Lu; Nicole Villafane; Turgut Dogruluk; Caitlin L Grzeskowiak; Kathleen Kong; Yiu Huen Tsang; Oksana Zagorodna; Angeliki Pantazi; Lixing Yang; Nicholas J Neill; Young Won Kim; Chad J Creighton; Roel G Verhaak; Gordon B Mills; Peter J Park; Raju Kucherlapati; Kenneth L Scott Journal: Cancer Res Date: 2017-05-16 Impact factor: 12.701